The IAS–USA Annual Update on HIV Management in Chicago, Illinois

Last Modified: Nov 11, 2025 @ 10:13 AM

Program Description

Join us for the highly anticipated and dynamic IAS–USA annual course in Chicago, Illinois, for the most current and clinically relevant information in HIV care. Don’t miss out on the opportunity to engage with faculty and peers and to stay at the forefront of what’s new in HIV management. This in-person live course will be at a new location at the David Rubenstein Forum at the University of Chicago.

This HIV course offers a timely and comprehensive update on the latest advancements and ongoing challenges in HIV care management. The program will highlight key findings from recent scientific conferences, alongside new data on HIV prevention and sexually transmitted infections (STIs). Through interactive, case-based discussions, participants will explore complex cases in antiretroviral therapy, including the implementation of long-acting drugs and the management of treatment failure. The agenda also includes emerging drugs and therapeutic strategies, practical guidance on immunizations for vaccine-preventable diseases in individuals with HIV, and best practices for delivering high-quality care to older adults. Attendees can expect cutting-edge updates on HIV cure research and future directions in the field.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV and other emerging challenges in HIV medicine. Information will be presented through a mix of didactic lectures, clinically relevant cases, and discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

• Implement the latest recommendations for initiating and changing antiretroviral therapy in clinical circumstances such as comorbid conditions, coinfections, pregnancy, and geriatric syndromes
• Describe the most current data from recent scientific conferences
• Initiate and monitor HIV prevention intervention strategies, including the use of long-acting injectable preexposure prophylaxis, in individuals at risk for HIV infection
• Apply the latest evidence-based treatment guidelines for common STIs
• Evaluate data on currently available and investigational new antiretroviral drugs, formulations, and strategies
• Identify recommended immunizations for individuals with HIV and implement best practices for vaccine-preventable disease prevention in this population
• Describe approaches to optimize care for aging individuals with HIV, including screening, treatment considerations, and management of comorbidities
• Describe advances in HIV cure research and assess their potential impact on the future of HIV care

Preliminary Topics

• Difficult cases in antiretroviral therapy
• New and investigational antiretroviral drugs and formulations
• Innovations in HIV prevention and STI management: what clinicians need to know
• Where are we now in HIV cure research?
• Immunization strategies for people with HIV
• Geriatric and HIV care: optimizing care for older adults
• “In Case You Missed It” overview of recent conference data, guidelines, and publications

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV infection
• Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 14 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.